Samsung Biologics’ Plant 5 Operations and PPGN Acquisition Benefits Gain Momentum; 1.95 Million Won Target Price Maintained
- Input
- 2026-11-17 08:57:10
- Updated
- 2026-11-17 08:57:10

[Financial News] Korea Investment & Securities forecast that Samsung Biologics would continue to grow its earnings over the medium to long term, driven by expanded production capacity and the effects of its acquisition.
However, it said that with earnings growth entering a slower phase than in the past, it would be necessary to look for additional signs of growth, such as resolving labor-management conflicts and winning large-scale contracts. It maintained its buy rating and set a target price of 1.95 million won.
On the 17th, Korea Investment & Securities said in an analysis report that it forecast Samsung Biologics’ revenue next year at 6.3297 trillion won, up 14% year on year. Operating profit is expected to rise 11% to 2.6203 trillion won. The operating margin is estimated at 41%.
Wi Haejoo, an analyst at Korea Investment & Securities, explained, “Since Plants 1–4 have already reached the point of full utilization in 2026, earnings growth will come from the ramp-up of Plant 5 and operations at the U.S. plant.”
The U.S. plant is expected to reach a utilization rate of around 50% and operate at around break-even (BEP), while Plant 5 is expected to begin producing commercial products in the second half of the year. Plant 5’s initial utilization rate is 16%, and its projected revenue is 289 billion won. A substantial contribution to earnings is expected from 2028.
The report also pointed to further growth potential from the acquisition of Polypeptide Group (PPGN). It forecast PPGN’s revenue next year at 832.5 billion won and operating profit at 100.5 billion won.
These figures represent increases of 14% and 54%, respectively, year on year. The report estimated that if PPGN were consolidated into Samsung Biologics’ results, revenue in 2027 would rise to around 7.2 trillion won and operating profit to around 2.7 trillion won.
In particular, the report highlighted the potential to link PPGN’s pipeline with its contract manufacturing (CMO) business. As of 2025, metabolic diseases accounted for 57% of PPGN’s revenue, and three of its 37 related projects had reached Phase 3 or later.
The researcher forecast, “If PPGN can sustain earnings improvement through commercialization or winning contracts for late-stage clinical metabolic disease assets, along with efficient operations, its standalone operating margin could improve to 20% in 2028.”
However, challenges remain before the earnings growth outlook can be realized. The report cited ongoing labor-management conflicts and concerns about delays in contract wins as key risk factors. Another variable is whether the U.S. Office of Management and Budget (OMB) will designate WuXi AppTec a company of concern. The relevant decision is expected to be announced on December 18, 2026.
The researcher emphasized, “Samsung Biologics can deliver results that exceed market expectations through the start of commercial production at Plant 5 and PPGN’s inclusion in consolidated results, but earnings growth is slowing compared with the past,” adding, “We need to look for signals such as resolving the labor-management conflict (a key risk) and securing large-scale contracts.”
[email protected] Kang Jung-mo Reporter